FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives
- Posted on August 26, 2026
- By Washington Post
- 0 Views
- 1 min read
In brief
Generating AI summary…
FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives
In trials, Revolution Medicines’ daraxonrasib nearly doubled average survival times for one of the deadliest cancers.
